Prostate Cancer Clinical Trial
Evaluation of the NV-VPAC1 Prostate Cancer (PCa) Urine Diagnostic Test in Subjects With Biopsy-confirmed Prostate Cancer, Benign Prostatic Hypertrophy, or Bladder/Kidney Stones.
Summary
This is a double-blind, study to evaluate the performance of NV-VPAC1 PCa Urine Diagnostic Test in three distinct populations being treated at the Intermountain Urology Clinic. The first population (positive control) is comprised of men with biopsy-confirmed PCa who are scheduled for prostatectomy. The second population (negative control) is comprised of men with benign prostatic hypertrophy (BPH) who are scheduled for transurethral resection of the prostate (TURP). The third population (negative control) is comprised of men or women with bladder/kidney stones who are scheduled for a cystoscopy.
Eligibility Criteria
Subjects with prostate cancer
Inclusion Criteria:
Males 18-80 years of age
Biopsy-confirmed prostate cancer
Scheduled within 2 weeks for prostatectomy
Signed informed consent
Exclusion Criteria:
Presence or history of another cancer diagnosis, with the exception of certain skin cancers
Currently treated with finasteride (Proscar®, Propecia®), dutasteride (Avodart®) or anti-androgen therapy (Lupron®)
Participated in a clinical study with an investigational drug within 2 weeks of the screening visit.
Subjects with benign prostatic hypertrophy
Inclusion Criteria:
Males 18-80 years of age
Diagnosis of BPH made by clinical symptoms (e.g., enlarged prostate, dribbling urine stream, frequent and urgent urination)
Scheduled within 2 weeks for TURP
Signed informed consent
Exclusion Criteria:
Presence or history of any cancer diagnosis, with the exception of certain skin cancers
Currently treated with finasteride (Proscar®, Propecia®) or dutasteride (Avodart®)
Participated in a clinical study with an investigational drug within 2 weeks of the screening visit.
Subjects with bladder/kidney stones
Inclusion Criteria:
Males or females 18-80 years of age
Diagnosed with bladder/kidney stones
Scheduled within 2 weeks for cystoscopy
Signed informed consent
Exclusion Criteria:
Presence or history of any cancer diagnosis, with the exception of certain skin cancers
Participated in a clinical study with an investigational drug within 2 weeks of the screening visit.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Murray Utah, 84107, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.